Inhibition of matrix metalloproteinases reduces ischemia-reperfusion acute kidney injury

Laboratory Investigation

Volumn 91, Issue 2, 2011, Pages 170-180

  Kunugi, Shinobu ^a   Shimizu, Akira ^a   Kuwahara, Naomi ^a   Du, Xuanyi ^a   Takahashi, Mikiko ^a   Terasaki, Yasuhiro ^a   Fujita, Emiko ^a   Mii, Akiko ^a   Nagasaka, Shinya ^a   Akimoto, Toshio ^a   Masuda, Yukinari ^a   Fukuda, Yuh ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

acute kidney injury; acute tubular injury; ischemia reperfusion; MMP inhibitor; MMP 2; MMP 9

Indexed keywords

CREATININE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; MINOCYCLINE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; KIDNEY INTERSTITIUM; KIDNEY ISCHEMIA; KIDNEY MEDULLA; KIDNEY TUBULE; KIDNEY TUBULE DAMAGE; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY;

EID: 79551583611     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.174     Document Type: Article

References (50)

1. Siegel NJ, Shah SV. Acute renal failure: directions for the next decade. J Am Soc Nephrol 2003;14:2176-2177.
2. Schrier RW, Wang W, Poole B, et al. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004;114:5-14.
3. Versteilen AM, Di Maggio F, Leemreis JR, et al. Molecular mechanisms of acute renal failure following ischemia/reperfusion. Int J Artif Organs 2004;27:1019-1029.
4. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005;365:417-430.
5. Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005;16:3365-3370.
6. Lieberthal W, Nigam SK. Acute renal failure. II. Experimental models of acute renal failure: imperfect but indispensable. Am J Physiol Renal Physiol 2000;278:F1-F12.
7. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003;14:2199-2210.
8. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006;17:1503-1520.
9. Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 2002;62: 1539-1549.
10. Molitoris BA, Sutton TA. Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int 2004;66:496-499.
11. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174.
12. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-573.
13. Rosell A, Lo EH. Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 2008;8:82-89.
14. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007;152:189-205.
15. Janssens S, Lijnen HR. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? Cardiovasc Res 2006;69:585-594.
16. Viappiani S, Sariahmetoglu M, Schulz R. The role of matrix metalloproteinase inhibitors in ischemia-reperfusion injury in the liver. Curr Pharm Des 2006;12:2923-2934.
17. Soccal PM, Gasche Y, Miniati DN, et al. Matrix metalloproteinase inhibition decreases ischemia-reperfusion injury after lung transplantation. Am J Transplant 2004;4:41-50.
18. Mathalone N, Lahat N, Rahat M.A., et al. The involvement of matrix metalloproteinases 2 and 9 in rat retinal ischemia. Graefes Arch Clin Exp Ophthalmol 2007;245:725-732.
19. Roach DM, Fitridge RA, Laws PE, et al. Up-regulation of MMP-2 and MMP-9 leads to degradation of type IV collagen during skeletal muscle reperfusion injury; protection by the MMP inhibitor, doxycycline. Eur J Vasc Endovasc Surg 2002;23:260-269.
20. Muhs BE, Plitas G, Delgado Y, et al. Temporal expression and activation of matrix metalloproteinases-2, -9, and membrane type 1-matrix metalloproteinase following acute hindlimb ischemia. J Surg Res 2003;111:8-15.
21. Basile DP, Fredrich K, Weihrauch D, et al. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. Am J Physiol Renal Physiol 2004;286:F893-F902.
22. Sutton TA, Kelly KJ, Mang HE, et al. Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 2005;288:F91-F97.
23. Caron A, Desrosiers RR, Béliveau R. Ischemia injury alters endothelial cell properties of kidney cortex: stimulation of MMP-9. Exp Cell Res 2005;310:105-116.
24. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007;292: F905-F911.
25. Jain S, Bicknell GR, Nicholson ML. Molecular changes in extracellular matrix turnover after renal ischaemia-reperfusion injury. Br J Surg 2000;87:1188-1192.
26. Ziswiler R, Daniel C, Franz E, et al. Renal matrix metalloproteinase activity is unaffected by experimental ischemia-reperfusion injury and matrix metalloproteinase inhibition does not alter outcome of renal function. Exp Nephrol 2001;9:118-124.
27. Bengatta S, Arnould C, Letavernier E, et al. MMP9 and SCF protect from apoptosis in acute kidney injury. J Am Soc Nephrol 2009;20: 787-797.
28. Itoh T, Ikeda T, Gomi H, et al. Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)- deficient mice. J Biol Chem 1997;272:22389-22392.
29. Kelly KJ, Sutton TA, Weathered N, et al. Minocycline inhibits apoptosis and inflammation in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 2004;287:F760-F766.
30. Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999;17: 768-774.
31. Henderson JA, He X, Jabbari E. Concurrent differentiation of marrow stromal cells to osteogenic and vasculogenic lineages. Macromol Biosci 2008;8:499-507.
32. Hentschel H, Walther P. Heterogenous distribution of glycoconjugates in the kidney of dogfish Scyliorhinus caniculus (L.) with reference to changes in the glycosylation pattern during ontogenetic development of the nephron. Anat Rec 1993;235:21-32.
33. Shimizu A, Masuda Y, Kitamura H, et al. Complement-mediated killing of mesangial cells in experimental glomerulonephritis: cell death by a combination of apoptosis and necrosis. Nephron 2000; 86:152-160.
34. Brooks C, Wei Q, Cho SG, et al. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest 2009;119:1275-1285.
35. Kunugi S, Fukuda Y, Ishizaki M, et al. Role of MMP-2 in alveolar epithelial cell repair after bleomycin administration in rabbits. Lab Invest 2001;81:1309-1318.
36. Zhao BQ, Tejima E, Lo EH. Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke 2007; 38(2 Suppl):748-752.
37. Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005;50:329-339.
38. Gu Z, Kaul M, Yan B, et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 2002;297: 1186-1190.
39. Lee SR, Lo EH. Induction of caspase-mediated cell death by matrix metalloproteinases in cerebral endothelial cells after hypoxiareoxygenation. J Cereb Blood Flow Metab 2004;24:720-727.
40. Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008;73:863-869.
41. Romanic AM, White RF, Arleth AJ, et al. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998;29:1020-1030.
42. Lindsey M, Wedin K, Brown MD, et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001;103: 2181-2187.
43. Romanic AM, Harrison SM, Bao W, et al. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res 2002;54:549-558.
44. Hamada T, Fondevila C, Busuttil RW, et al. Metalloproteinase-9 deficiency protects against hepatic ischemia/reperfusion injury. Hepatology 2008;47:186-198.
45. Rosell A, Cuadrado E, Ortega-Aznar A, et al. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008;39:1121-1126.
46. Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 2008;19:34-41.
47. Gill SE, Parks WC. Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol 2008;40:1334-1347.
48. Korpos E, Wu C, Sorokin L. Multiple roles of the extracellular matrix in inflammation. Curr Pharm Des 2009;15:1349-1357.
49. Fukuda Y, Ishizaki M, Kudoh S, et al. Localization of matrix metalloproteinases- 1, -2 and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab Invest 1998;78:687-698.
50. Fukuda Y, Ishizaki M, Okada Y, et al. Matrix metalloproteinases and tissue inhibitor of metalloproteinases-2 in fetal rabbit lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L555-L561.